RESEARCH PEPTIDE • INVESTIGATIONAL COMPOUND
Retatrutide
Triple Receptor Agonist
$299
FOR RESEARCH USE ONLY. This product is intended for laboratory and research applications only. Not for human consumption, clinical, diagnostic, or therapeutic use. This is an investigational compound currently in clinical trials without regulatory approval. Purchaser assumes all liability.
Research Overview
Retatrutide is an investigational peptide agonist that activates three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This novel triple receptor mechanism represents a unique approach in metabolic research.
Currently in Phase 3 clinical trials, retatrutide is being studied for multiple metabolic conditions in controlled research settings. As an investigational compound, it has not received regulatory approval for any clinical indication.
Research Applications
Metabolic Pathway Studies
Laboratory research examines simultaneous activation of GIP, GLP-1, and glucagon receptors and their synergistic effects on cellular metabolism and energy homeostasis.
Energy Balance Research
Preclinical and clinical trial data investigate effects on energy expenditure, substrate utilization, and metabolic rate modulation in controlled study environments.
Glucose Metabolism Models
Research protocols examine insulin secretion, glucose homeostasis, and pancreatic beta-cell function in various experimental systems.
Clinical Trial Research
Ongoing Phase 3 trials (TRIUMPH program) investigate multiple endpoints including body composition, cardiovascular markers, and metabolic parameters.
Specifications
Storage & Handling
Store lyophilized peptide at 2-8°C. Do not freeze. Protect from light and moisture. Once reconstituted, use immediately or store at 2-8°C for short-term use according to your research protocol.
Reconstitute with sterile bacteriostatic water or appropriate buffer. Use aseptic technique. This investigational compound should be handled with appropriate safety protocols in qualified research facilities only.
Selected References
1. Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389(6):514-526.
2. Eli Lilly and Company. "TRIUMPH-4 Phase 3 Clinical Trial Results." Press Release, December 2025.
3. ClinicalTrials.gov. "Multiple Phase 3 trials of retatrutide in metabolic conditions." 2024-2025.